查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870233

脉络膜新生血管市场：依疗法、药物类别、疾病类型、病变类型、治疗阶段、通路和最终用户划分－2025-2032年全球预测

Choroidal Neovascularization Market by Treatment Type, Drug Class, Disease Type, Lesion Type, Line Of Therapy, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，脉络膜新生血管市场将成长至 116.9 亿美元，复合年增长率为 7.85%。

关键市场统计数据
基准年 2024 63.8亿美元
预计年份：2025年 68.8亿美元
预测年份 2032 116.9亿美元
复合年增长率 (%) 7.85%

对脉络膜新生血管（CNV）进行清晰全面的概述：系统性说明其临床特征、诊断技术进展和不断发展的治疗现状。

脉络膜新生血管（CNV）是影响脉络膜-视网膜介面最严重的併发症之一，可导致视力丧失、长期併发症以及医疗资源的浪费。本文摘要了CNV的临床特征、诊断流程以及影响其临床和商业格局的当代诊疗标准。多模态影像和早期检测技术的进步使得更及时的干预成为可能，从而能够重建患者病史，改变疾病进展轨迹和治疗结果。然而，这些诊断技术的进步也增加了眼科医师、视网膜专家和门诊手术中心之间诊疗协调的复杂性。

从多学科观点探讨科学、临床和治疗模式的变革性转变，这些转变正在重塑脉络膜新生血管（CNV）的治疗范式和相关人员的期望。

在科学创新、医疗服务模式变革以及对以患者为中心的治疗结果的重新关注的推动下，脉络膜新生血管（CNV）的治疗格局正在经历变革性变化。抗血管内皮生长因子（VEGF）药物的生物学改进和分子工程改造，提高了疗效并改善了安全性，促使临床医生重新考虑给药间隔和随访方案。同时，真实世界数据和基于註册登记的见解，为治疗提供了更精准的指南，尤其适用于疾病形态复杂或对一线治疗反应不佳的患者。这些临床趋势与营运模式的改变密切相关。虽然门诊手术中心和眼科诊所越来越具备进行复杂玻璃体内注射治疗的能力，但医院系统在严重病例的治疗中仍发挥核心作用。

CNV Therapeutics公司2025年美国关税环境对供应链韧性、製造地和商业协议影响的策略分析

2025年美国关税调整的累积影响正在改变CNV疗法及相关医疗设备的成本结构与供应链动态。进口生物製药原料、包装材料和专用给药装置的关税调整增加了部分製造商的采购成本，并促使他们重新检视筹资策略。因此，一些公司正在加快关键生物製药生产流程的在地化进程，并实现供应商多元化，涵盖多个地区，以降低贸易政策波动带来的风险。这种供应链重组可能会导致前置作业时间延长和短期库存失衡，因此需要积极主动的库存管理和分销计划。

透过深度細項分析，将治疗类型、分子类别、病理/疾病表型、临床环境和通路联繫起来，从而指导可行的临床和商业策略。

細項分析揭示了治疗方案、分子分型、临床症状、病变特征、治疗线、分销管道和终端用户类型如何共同塑造需求趋势和治疗路径。治疗类型仍然是关键因素，其中抗VEGF疗法主导治疗决策。阿维西普和雷珠单抗等药物之间的分子差异会影响给药间隔和患者追踪。Bevacizumab由于其在某些情况下的成本驱动作用而仍然重要，而具有改进分子结构的新型药物旨在提高疗效和安全性。动态疗法与抗VEGF药物的联合治疗选择性地用于某些难治性或非典型病例，而基于维替泊芬的独立动态疗法在某些病变亚型中仍然发挥作用。

从区域策略观点出发，协调全球主要医疗区域在脉络丛新生血管（CNV）治疗方面存在的临床实践差异、监管差异和供应链现实问题。

区域趋势对美洲、欧洲、中东和非洲以及亚太地区的临床实践、监管路径和商业模式均有显着影响。在美洲，先进的视网膜护理基础设施和都市区对创新技术的积极应用正在塑造市场发展，而支付方的复杂性和报销政策的不均衡则造成了不同的准入途径，需要製定量身定制的市场进入策略。同时，欧洲、中东和非洲地区的管理体制和医疗保健资金筹措模式各不相同，有些市场正在快速接受生物製药，而有些市场则受到预算上限的限制。应对这些差异需要各国采取相应的措施，并收集证据以支持报销申请。亚太地区呈现出复杂的格局，庞大的患者群体和不断增长的专科医生能力与采购惯例、价格敏感度和监管时限的差异并存。在地化生产和区域伙伴关係是商业性成功的关键因素。

公司层面的竞争动态强调分子创新、真实世界数据、病患倡议和供应链韧性，以此作为 CNV 差异化的基础。

公司层面的关键趋势集中在分子设计、生命週期管理和患者支援基础设施的创新。研发人员正在开发新一代抗VEGF药物，以延长疗效、优化安全性，并透过独特的作用机制和给药方式实现差异化。策略重点包括建立可靠的真实世界证据项目以证明药物的相对疗效，建立全面的患者支持和依从性服务，以及投资于生产冗余以降低供应风险。随着创新公司寻求简化产品获取途径并克服处理复杂生物製药相关的物流挑战，它们与专业经销商和医院系统之间的合作变得日益重要。

为促进CNV成功，产业领导者可提出的切实可行的优先建议：协调证据产生、生产韧性、准入计画和支付方参与。

为了将本报告的研究结果转化为实际营运优势，产业领导者应优先考虑一系列切实可行的倡议，使临床差异化与商业性执行相契合。首先，应将实证研究的重点放在头对头研究和真实世界对比研究上，以明确不同病变亚型和治疗方案的治疗定位。此类证据将有助于改善与支付方的沟通，并增强临床医生的信心。其次，应投资于灵活的生产製造和区域灌装包装能力，以降低关税引发的供应中断风险，并缩短关键物料的前置作业时间。第三，应根据每个通路和终端用户的实际情况，量身定制准入和患者援助计划，并确保门诊手术中心和眼科诊所获得所需的后勤和教育支持，从而优化患者依从性和治疗效果。

本分析所依据的调查方法是一种混合方法研究，它将主要相关利益者访谈与系统的二手证据审查相结合，并采用严格的检验和品管。

本分析的调查方法融合了第一手和第二手研究手段，以确保其稳健性、有效性和实用性。第一手研究包括对视网膜专科医生、医院药房主任、诊所管理人员和支付方进行半结构式访谈，以收集有关治疗决策、运作限制和就医难的第一手资料。第二手研究包括对同侪审查的临床文献、监管申报文件、临床试验註册库和已发布的专业学会指南进行系统性回顾，以梳理治疗模式和特异性病理的治疗结果。资料三角验证法将定性研究结果与已发表的临床检验相结合，以验证新出现的主题并识别临床试验人群与真实世界实践之间的差异。

整合临床创新、业务永续营运和支付方合作策略，进行权威分析，将CNV治疗进展转化为持续的患者和商业性效益。

总之，脉络膜新生血管仍是一个科学和商业性快速发展的领域，临床创新、供应链策略和支付方合作的交汇点将决定患者的治疗机会和治疗效果。抗VEGF生物製剂和辅助性治疗的进步正在推动更个人化的治疗模式，但这些机会必须辅以对实证医学、生产韧性和有针对性的准入计画的投入。关税趋势和区域监管的复杂性增加了营运风险，企业可以透过采购多元化、区域伙伴关係和积极的支付方策略来降低这些风险。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 将人工智慧影像分析技术应用于早期CNV检测与监测
  • 开发一种缓释型玻璃体内植入，以减轻脉络膜新生血管患者的治疗负担
  • 针对血管内皮生长因子路径治疗CNV的基因编辑疗法的出现
  • 提高生物相似抗 VEGF 药物的使用率，以提高 CNV 治疗的成本效益和可近性。
  • 引入远距眼科平台，用于远端监测和管理脉络膜新生血管（CNV）进展

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 脉络膜新生血管市场依治疗方法划分

  • 抗 VEGF 疗法
    • 阿黄曲普
    • Bevacizumab
    • 布罗卢西珠单抗
    • 康柏西普
    • 雷珠单抗
  • 联合治疗
    • 动态疗法+抗VEGF疗法
  • 动态疗法
    • 维替泊芬

9. 脉络膜新生血管市场（依药物类别划分）

  • 融合蛋白
  • 单株抗体

第十章 脉络膜新生血管市场依疾病类型划分

  • 新生血管性老龄化黄斑部病变（AMD）
  • 病理性近视

第十一章 脉络膜新生血管市场（依病变类型划分）

  • 经典 CNV
  • 混合拷贝数变异
  • 潜在拷贝数变异

第十二章 脉络膜新生血管市场依治疗线划分

  • 一线治疗
  • 二级治疗
  • 三线治疗

第十三章 脉络膜新生血管市场依通路划分

  • 医院药房
  • 零售药房

第十四章 脉络膜新生血管市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 眼科诊所

第十五章 脉络膜新生血管市场（依地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 脉络膜新生血管市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国脉络膜新生血管市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Regeneron Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Bayer AG
    • Sanwa Kagaku Kenkyusho Co. Ltd.
Product Code: MRR-976C0ED91BDE

The Choroidal Neovascularization Market is projected to grow by USD 11.69 billion at a CAGR of 7.85% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 6.38 billion
Estimated Year [2025] USD 6.88 billion
Forecast Year [2032] USD 11.69 billion
CAGR (%) 7.85%

A clear and comprehensive introduction to choroidal neovascularization that frames clinical characteristics, diagnostic improvements, and the evolving treatment landscape

Choroidal neovascularization (CNV) remains one of the most consequential complications affecting the choroid-retina interface, with implications for vision loss, long-term morbidity, and healthcare resource allocation. This introduction distills the clinical characteristics, diagnostic pathways, and contemporary standards of care that frame the therapeutic and commercial environment. Advances in multimodal imaging and earlier detection have reshaped patient journeys, enabling more timely interventions that alter disease trajectories and patient outcomes. These diagnostic gains, however, have increased the complexity of care coordination among ophthalmologists, retinal specialists, and ambulatory surgical centers.

Concurrently, treatment paradigms have evolved from focal therapies toward sustained biologic modulation of angiogenic pathways. Anti-VEGF agents have become central to clinical practice, while adjunctive approaches, including combination regimens and photodynamic therapy, persist in specific phenotypes or refractory cases. Payer policies and reimbursement coding have not always moved in lockstep with clinical innovation, creating variability in access and treatment continuity. As a result, stakeholders must navigate an intricate interplay between therapeutic efficacy, delivery logistics, and economic considerations when designing clinical programs and commercial strategies. This overview establishes the clinical and operational context necessary to evaluate subsequent sections on market shifts, segmentation insights, and strategic recommendations.

An interdisciplinary view of transformative scientific, clinical, and delivery-model shifts reshaping CNV treatment paradigms and stakeholder expectations

The landscape for CNV treatment is experiencing transformative shifts driven by scientific innovation, changing care delivery models, and a renewed focus on patient-centric outcomes. Biologic refinement and molecular engineering of anti-VEGF agents have extended durability and modified safety profiles, prompting clinicians to rethink dosing intervals and follow-up regimens. At the same time, real-world evidence and registry-driven insights are informing more nuanced therapy selection, especially for patients with complex lesion morphologies or those who demonstrate suboptimal response to first-line agents. These clinical dynamics are intersecting with operational changes: ambulatory surgical centers and ophthalmology clinics are increasingly equipped to deliver complex intravitreal therapies, while hospital systems continue to play a central role for higher-acuity presentations.

In parallel, payer scrutiny and value-based contracting conversations are influencing formulary positioning and access pathways. Manufacturers are responding with differentiated patient support programs and innovative distribution partnerships to reduce barriers to adherence. Technological advances in imaging and telemedicine have further enabled remote monitoring, which can reduce patient burden and improve adherence, but also require investment in interoperable systems and clinician training. Taken together, these shifts demand cross-functional strategies that align clinical differentiation, supply chain reliability, and stakeholder engagement to capitalize on therapeutic advances while safeguarding patient access and continuity of care.

A strategic analysis of how the 2025 United States tariff environment is reshaping supply chain resilience, manufacturing footprints, and commercial contracting for CNV therapies

The cumulative impact of United States tariff changes in 2025 is altering cost structures and supply chain dynamics that underpin CNV therapeutics and related medical devices. Tariff adjustments on imported biologic components, packaging materials, and specialized delivery devices have elevated sourcing costs for certain manufacturers, prompting them to reassess procurement strategies. As a result, some firms are accelerating initiatives to localize critical steps of biologic manufacturing or to diversify supplier bases across multiple geographies to mitigate exposure to trade policy volatility. This reconfiguration of supply chains can increase lead times and create short-term inventory imbalances that require proactive inventory and distribution planning.

Moreover, tariff-driven cost pressures are influencing the calculus around pricing, patient assistance programs, and contracting with payers. Health systems and distributors may face incremental logistical costs that translate into negotiations over reimbursement and formulary placement. In response, manufacturers are exploring near-term tactics such as hedging procurement contracts, modifying packaging to reduce tariffable components, and investing in regional fill-and-finish capacity. While these steps can stabilize supply, they also require capital allocation and regulatory alignment. Ultimately, the tariff environment is accelerating strategic decisions around manufacturing footprint, commercial contracting, and collaboration with end users to preserve timely access for patients while maintaining sustainable commercial models.

Deep segmentation insights linking treatment types, molecular classes, lesion and disease phenotypes, care settings, and distribution pathways to actionable clinical and commercial strategies

Segmentation analysis reveals how therapeutic choices, molecular classes, clinical presentations, lesion characteristics, lines of therapy, distribution channels, and end-user types collectively shape demand dynamics and care pathways. Treatment type remains a primary axis: anti-VEGF therapy dominates therapeutic decision-making, with molecule-level differentiation among agents such as aflibercept and ranibizumab that influence dosing cadence and patient follow-up. Bevacizumab retains relevance through cost-driven use in certain settings, while newer entrants with modified molecular structures aim to extend durability or alter safety profiles. Combination approaches that integrate photodynamic therapy with anti-VEGF agents are selectively employed for specific refractory or atypical presentations, and standalone photodynamic therapy, anchored by verteporfin, maintains a role in certain lesion subtypes.

Drug class segmentation highlights the operational and regulatory differences between fusion proteins and monoclonal antibodies; manufacturing complexity, cold-chain requirements, and patent landscapes differ across these classes and inform commercialization strategies. Disease-type distinctions between neovascular age-related macular degeneration and pathologic myopia dictate patient populations, natural history, and therapeutic responsiveness, requiring tailored clinical protocols. Lesion-type categories such as classic, mixed, and occult choroidal neovascularization present unique prognostic and treatment-response considerations that clinicians factor into initial therapy selection and monitoring frequency. Line-of-therapy segmentation underscores differences in goals between first-line interventions aimed at rapid disease control and second- or third-line approaches focused on refractory disease management. Distribution channel nuances between hospital and retail pharmacies affect dispensing workflows, reimbursement processes, and patient access points. Finally, end-user segmentation-spanning ambulatory surgical centers, hospitals, and ophthalmology clinics-captures the diversity of care settings where CNV treatments are delivered, each with distinct operational constraints, clinician expertise, and patient throughput considerations. Synthesizing these segmentation layers enables stakeholders to align clinical trial design, commercial messaging, and service delivery models to specific patient and provider contexts.

Regional strategic perspectives that reconcile clinical practice diversity, regulatory variation, and supply chain realities across major global healthcare regions for CNV

Regional dynamics exert a significant influence on clinical practice, regulatory pathways, and commercial models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, market evolution is shaped by advanced retinal care infrastructure and strong adoption of innovation in urban centers, while payer complexity and heterogeneous reimbursement policies create variable access pathways and necessitate tailored market access strategies. In contrast, Europe, Middle East & Africa encompasses diverse regulatory regimes and healthcare financing models, with some markets demonstrating rapid uptake of advanced biologics and others constrained by budget ceilings; these differences require nuanced country-level engagement and evidence generation to support reimbursement dossiers. Asia-Pacific presents a heterogeneous landscape where high-volume patient populations and growing specialist capacity coexist with differences in procurement practices, pricing sensitivity, and regulatory timelines; local manufacturing and regional partnerships can be decisive factors in commercial success.

Across these regions, differences in clinical practice patterns, imaging availability, and end-user capabilities influence treatment pathways and patient outcomes. Regional regulatory policies around biologics, biosimilars, and import controls interact with logistical realities to shape supply chain design and launch sequencing. Therefore, stakeholders must adopt regionally differentiated strategies that integrate health-economic evidence, local real-world data, and clinician engagement plans to ensure that therapeutic innovations translate into sustained clinical adoption and patient benefits.

Company-level competitive dynamics emphasizing molecular innovation, real-world evidence, patient support, and supply chain resilience as bases for differentiation in CNV

Key company-level dynamics center on innovation in molecule design, lifecycle management, and patient support infrastructure. Developers are advancing next-generation anti-VEGF agents that seek to extend durability, optimize safety, and differentiate via unique mechanisms or delivery formats. Strategic priorities include building robust real-world evidence programs to demonstrate comparative effectiveness, establishing comprehensive patient support and adherence services, and investing in manufacturing redundancy to reduce supply risk. Partnerships between innovator firms and specialty distributors or hospital systems are becoming more salient as companies seek to streamline product access and overcome logistical hurdles tied to complex biologic handling.

Competitive differentiation increasingly depends on the ability to demonstrate outcomes in varied lesion types and patient subsets, to engage payers through outcome-based arrangements, and to enable clinicians with practical tools for treatment decisions and imaging interpretation. Companies that successfully integrate clinical development with targeted health-economic data and that invest in scalable support programs for diverse care settings are best positioned to navigate reimbursement negotiations and to sustain adoption in the face of biosimilar or alternative therapeutic entrants. Observing these company behaviors provides a roadmap for supply chain investment, evidence-generation priorities, and commercial execution.

Actionable, prioritized recommendations for industry leaders to align evidence generation, manufacturing resilience, access programs, and payer engagement for CNV success

To translate the report's insights into operational advantage, industry leaders should prioritize a set of actionable initiatives that align clinical differentiation with commercial execution. First, concentrate evidence-generation efforts on head-to-head and real-world comparative studies that clarify therapeutic positioning across lesion subtypes and lines of therapy; such evidence will improve payer dialogues and clinician confidence. Second, invest in flexible manufacturing and regional fill-and-finish capabilities to reduce exposure to tariff-driven disruptions and to shorten lead times for critical supplies. Third, tailor access and patient support programs to the realities of different distribution channels and end users, ensuring that ambulatory surgical centers and ophthalmology clinics receive logistical and educational support to optimize adherence and outcomes.

Additionally, explore innovative contracting models with payers that tie reimbursement to measurable clinical outcomes, and deploy digital monitoring tools to support remote follow-up and adherence. Foster targeted partnerships with regional stakeholders to address regulatory and procurement heterogeneity, and design product launch sequencing that reflects regional readiness and infrastructure capacity. Finally, translate clinical differentiation into pragmatic clinician-facing resources-such as dosing algorithms and imaging interpretation guides-to reduce variation in care and to accelerate adoption in complex patient populations.

A rigorous, mixed-methods research methodology combining primary stakeholder interviews and systematic secondary evidence review with robust triangulation and quality controls

The research methodology underpinning this analysis integrates primary and secondary approaches to ensure robustness, validity, and practical relevance. Primary research involved semi-structured interviews with retina specialists, hospital pharmacy directors, clinic administrators, and payers to capture firsthand perspectives on treatment decision-making, operational constraints, and access challenges. Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory filings, clinical trial registries, and publicly available guidance from professional societies to map treatment paradigms and lesion-specific outcomes. Data triangulation combined qualitative insights with published clinical evidence to validate emergent themes and to surface discrepancies between clinical trial populations and real-world practice.

Quality control measures included cross-validation of interview findings across multiple stakeholder cohorts, transparent documentation of inclusion criteria for secondary sources, and sensitivity checks to assess the robustness of strategic conclusions. The methodology explicitly acknowledges limitations related to regional heterogeneity and evolving regulatory landscapes; where data gaps exist, the analysis highlights areas requiring further primary evidence generation. Ethical standards for primary research were maintained, with informed consent obtained for interviews and confidentiality assured for proprietary disclosures. This mixed-methods approach supports a balanced, evidence-informed perspective that is actionable for clinical, commercial, and policy stakeholders.

A conclusive synthesis of clinical innovation, operational resilience, and payer-aligned strategies to convert therapeutic advances in CNV into sustained patient and commercial outcomes

In conclusion, choroidal neovascularization remains a domain of rapid scientific and commercial evolution where clinical innovation, supply chain strategy, and payer engagement intersect to determine patient access and therapeutic success. Advances in anti-VEGF biology and adjunctive therapies are enabling more personalized treatment paradigms, but these opportunities must be matched by investments in evidence generation, manufacturing resilience, and targeted access programs. Tariff dynamics and regional regulatory complexity add layers of operational risk that companies can mitigate through diversified sourcing, regional partnerships, and proactive payer strategies.

Ultimately, organizations that synchronize clinical differentiation with pragmatic execution-through rigorous real-world studies, clinician-enabled adoption tools, and flexible commercial models-will achieve sustained adoption and deliver measurable patient benefit. The strategic recommendations and segmentation insights presented herein provide a framework to prioritize initiatives, align cross-functional teams, and convert clinical promise into enduring therapeutic impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence image analysis in early CNV detection and monitoring
  • 5.2. Development of sustained-release intravitreal implants to reduce treatment burden in CNV patients
  • 5.3. Emergence of gene editing therapies targeting vascular endothelial growth factor pathways for CNV
  • 5.4. Increasing uptake of biosimilar anti-VEGF agents to improve affordability and access for CNV care
  • 5.5. Adoption of teleophthalmology platforms for remote monitoring and management of CNV progression

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Choroidal Neovascularization Market, by Treatment Type

  • 8.1. Anti-Vegf Therapy
    • 8.1.1. Aflibercept
    • 8.1.2. Bevacizumab
    • 8.1.3. Brolucizumab
    • 8.1.4. Conbercept
    • 8.1.5. Ranibizumab
  • 8.2. Combination Therapy
    • 8.2.1. Photodynamic + Anti-Vegf
  • 8.3. Photodynamic Therapy
    • 8.3.1. Verteporfin

9. Choroidal Neovascularization Market, by Drug Class

  • 9.1. Fusion Proteins
  • 9.2. Monoclonal Antibodies

10. Choroidal Neovascularization Market, by Disease Type

  • 10.1. Neovascular Amd
  • 10.2. Pathologic Myopia

11. Choroidal Neovascularization Market, by Lesion Type

  • 11.1. Classic Cnv
  • 11.2. Mixed Cnv
  • 11.3. Occult Cnv

12. Choroidal Neovascularization Market, by Line Of Therapy

  • 12.1. First Line
  • 12.2. Second Line
  • 12.3. Third Line

13. Choroidal Neovascularization Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Retail Pharmacy

14. Choroidal Neovascularization Market, by End User

  • 14.1. Ambulatory Surgical Centers
  • 14.2. Hospitals
  • 14.3. Ophthalmology Clinics

15. Choroidal Neovascularization Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Choroidal Neovascularization Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Choroidal Neovascularization Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Regeneron Pharmaceuticals, Inc.
    • 18.3.2. F. Hoffmann-La Roche Ltd
    • 18.3.3. Novartis AG
    • 18.3.4. Bayer AG
    • 18.3.5. Sanwa Kagaku Kenkyusho Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. CHOROIDAL NEOVASCULARIZATION MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. CHOROIDAL NEOVASCULARIZATION MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CHOROIDAL NEOVASCULARIZATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CONBERCEPT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC + ANTI-VEGF, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY VERTEPORFIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FUSION PROTEINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY NEOVASCULAR AMD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PATHOLOGIC MYOPIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY CLASSIC CNV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY MIXED CNV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OCCULT CNV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY OPHTHALMOLOGY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISEASE TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LESION TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY ANTI-VEGF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY COMBINATION THERAPY, 2025-2032 (USD MILLION)
  • TABLE 295. MIDDLE EAST CHOROIDAL NEOVASCULARIZATION MARKET SIZE, BY PHOTODYNAMIC THERAPY, 2018-2024 (